Addressing the Role of Glycated Albumin Non-Enzymatic Glycation in Retinal Vascular Diseases: GLY-230
Time: 2:15 pm
day: Day One
Details:
- Compelling preclinical evidence of reversal of diabetic retinal vascular disease pathologies
- Sharing a reversal in abnormal biomarkers (including VEGF) with a small molecule given orally and/or with multimodal administration possibilities
- GLY-230 reverses in the documented direct pathogenic actions of glycated albumin (GA) and decreases in generation of AGEs which are also pathogenic in RVD
